Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis

Trial Profile

A Phase III, Multicenter, Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Alcaftadine/ketorolac (Primary) ; Alcaftadine
  • Indications Allergic conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Ajanta Pharma
  • Most Recent Events

    • 13 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top